Using a retrospective cohort design, the team evaluated medication regimen complexity alongside rehospitalization outcomes. Rather than treating “number of prescriptions” as the sole factor, the analysis emphasized the multifaceted nature of regimen complexity—such as dosing schedules and the practical effort required to follow therapy correctly over time.

The study’s cohort comprised older participants with chronic kidney disease, reflecting a population where polypharmacy is common and physiological changes can alter how drugs behave in the body. In this setting, even small adherence difficulties can cascade into worsening symptoms, preventable complications, and ultimately emergency care.

Technically, the researchers linked regimen complexity measures to rehospitalization risk, controlling for relevant patient characteristics that could also influence outcomes. This approach strengthens the causal interpretation typical of observational studies, even though it cannot fully replace randomized trials.

Clinically, the results suggest that greater regimen complexity is not merely an administrative burden; it may carry measurable prognostic value for near-term health trajectories. For older adults, complex schedules can increase the probability of missed doses, dosing errors, or confusion between medications—factors that can undermine treatment goals.

The implications extend beyond adherence alone. Medication complexity can interact with kidney function decline, drug–drug interactions, and fluctuating tolerability, all of which are common in chronic kidney disease management. When these pressures accumulate, the risk of rehospitalization may rise.

For clinicians, the findings reinforce the value of medication reviews and regimen simplification strategies, including deprescribing where appropriate and consolidating dosing schedules when possible. For health systems, it supports integrating complexity assessments into routine geriatric and nephrology care pathways.

Taken together, the work positions medication regimen complexity as a modifiable risk signal. If future prospective studies confirm these patterns, clinicians could use complexity metrics to identify patients most likely to benefit from targeted interventions—potentially reducing avoidable readmissions.

Subject of Research: Older adults with chronic kidney disease; medication regimen complexity and rehospitalization.

Article Title: Evaluation of medication regimen complexity and rehospitalization in older adults with chronic kidney disease: a retrospective cohort study.

Article References: Albayrak, A., Başarır, C.N. & Altuntaş, A. (2026). BMC Geriatrics. https://doi.org/10.1186/s12877-026-07986-7

Image Credits: AI Generated

DOI: 10.1186/s12877-026-07986-7

The technology underlying this oral weekly pill is the result of over a decade of meticulous research and engineering aimed at circumventing the obstacles posed by frequent dosing schedules. The capsule itself resembles a large multivitamin in size but boasts a sophisticated mechanical design: upon ingestion, it unfolds into a star shape comprised of six radial arms. These arms anchor the device within the stomach by remaining too large to pass through the pyloric sphincter, the natural gateway to the intestines, thereby creating a biocompatible depot that releases medication slowly over several days. This mechanism ensures prolonged presence in the gastric environment, circumventing rapid transit into the intestines and enhancing localized drug delivery.

The most recent phase 3 clinical trial focused on schizophrenia, employing risperidone—an antipsychotic drug commonly taken daily to manage this debilitating neuropsychiatric disorder. Conducted across five sites in the United States with 83 enrolled patients, the study evaluated the pharmacokinetics and therapeutic efficacy of the weekly oral capsule formulation, known as LYN-005. Patients who completed the trial took one capsule per week for five consecutive weeks, and plasma drug concentrations were systematically measured to assess drug release dynamics and stability. The trial established that medication levels achieved with once-weekly dosing were not only therapeutically effective but demonstrated less pharmacokinetic variability compared to conventional daily pills.

The capsule’s unique geometry and material composition, informed by mechanical and biomedical engineering principles, are central to its successful function. Initially folded for ease of swallowing, the capsule quickly unfolds upon capsule coating dissolution in the acidic environment of the stomach. The arms, fabricated from biocompatible polymers engineered for controlled biodegradation, maintain structural integrity for approximately seven days. Subsequently, these arms fragment into smaller sections that can safely pass through the digestive tract and be excreted naturally, thereby mitigating any potential risk of gastrointestinal obstruction or discomfort. This design enables sustained drug release while preserving patient safety over prolonged gastrointestinal residency.

By leveraging this prolonged gastric retention, the device establishes a controlled-release drug depot. The risperidone embedded within the arms diffuses at a carefully calibrated rate, maintaining stable plasma concentrations optimal for symptom control. Such consistent drug exposure is crucial for schizophrenia management, as fluctuations can precipitate relapse or aggravate disease severity. The device’s ability to deliver medication orally addresses a significant patient preference barrier, given that alternative long-acting formulations typically require biweekly to bimonthly injections administered by healthcare professionals. This innovation thus expands patient autonomy while preserving therapeutic rigor.

Importantly, the clinical evaluations revealed that the once-weekly capsule was effective at sustaining symptom remission comparable to standard daily dosing, as quantified by the Positive and Negative Syndrome Scale (PANSS) scores. Patients’ clinical symptoms remained stable throughout the study’s duration without evidence of deterioration or breakthrough psychosis. Moreover, the safety profile was favorable, with minimal adverse effects limited primarily to mild and transient gastrointestinal symptoms such as acid reflux and constipation, which resolved with continued use. These findings underscore the capsule’s acceptability and clinical viability as a transformative drug delivery modality.

This research represents a pioneering intersection of mechanical engineering, gastroenterology, and psychiatric medicine, highlighting the transformational potential of advanced drug delivery technologies. The multidisciplinary team, including clinicians, pharmacometrists, and engineers, have meticulously optimized device design, drug loading processes, and clinical protocols to ensure reproducibility and scalability. The implications of this technology extend beyond schizophrenia; the platform offers a generalizable approach for sustained oral delivery of diverse pharmaceuticals that currently rely on frequent dosing schedules, broadening treatment options across multiple therapeutic areas.

The innovation stems from MIT’s rich heritage in biomedical devices, spearheaded by Giovanni Traverso, whose work has progressively matured from proof-of-concept prototypes to clinical-grade products. Notably, the conception of the star-shaped gastroretentive device dates back to 2016, with subsequent refinement enabling the current commercial incarnation. The collaboration with Lyndra Therapeutics has been instrumental in translating academic prototypes into a viable pharmaceutical product, demonstrating the promise of university spinouts in accelerating healthcare breakthroughs.

Looking forward, the research team plans to conduct larger-scale phase 3 trials to validate efficacy and safety further and support regulatory submissions aimed at bringing this therapy to market. Additionally, early-phase studies are underway evaluating the capsule’s application for alternative agents including hormonal contraceptives, indicating the versatility of the platform. Such expansion could significantly alleviate medication adherence challenges in various clinical contexts, transforming oral dosing paradigms with sustained-release, patient-friendly formulations.

The advent of this ingestible, star-shaped capsule embodies a leap forward in personalized and precision medicine, merging engineering innovation with clinical insights to address one of the most stubborn obstacles in chronic disease management: consistent medication adherence. As healthcare systems worldwide grapple with improving patient outcomes and reducing hospitalizations related to nonadherence, technologies of this nature offer a compelling blueprint for the future of therapeutics. By combining ease of use with advanced drug delivery kinetics, this once-weekly oral capsule may soon redefine standards of care for schizophrenia and beyond.

In conclusion, this technological milestone not only validates the feasibility of stomach-resident drug depots but also marks a tangible step toward reducing patient burden and improving long-term treatment success. It exemplifies how cross-disciplinary collaboration can solve complex healthcare challenges through ingenious device engineering, rigorous clinical assessment, and patient-centered design. If future studies uphold these encouraging results, such technologies could herald a new era in oral pharmacotherapy, characterized by sustained delivery, improved adherence, and superior patient quality of life.

Subject of Research: People

Article Title: Long-acting oral weekly risperidone (LYN-005) for schizophrenia in the USA (STARLYNG-1): a multicentre, open-label, non-randomised phase 3 trial

News Publication Date: 10-Jun-2025

Image Credits: Adam Glanzman

Keywords: Drug delivery, Drug delivery systems, Pharmaceuticals, Health and medicine, Psychological science, Schizophrenia, Psychotic disorders

A comprehensive study conducted by researchers affiliated with Mass General Brigham, published recently in the Journal of the American Medical Association (JAMA), systematically evaluates the scope and impact of insurer exits from the Medicare Part D program. The investigation utilized extensive datasets provided by the Centers for Medicare & Medicaid Services (CMS), spanning from 2018 through 2024. According to the findings, the number of Medicare beneficiaries affected by insurer withdrawal surged dramatically, reaching 2.9 million individuals between 2024 and 2025. This figure starkly contrasts with annual losses ranging between 0.1% and 2.3% from 2018 to 2023, revealing an alarming 7.5% loss rate in 2024 alone.

These insurer exits are intricately linked to the structural modifications introduced under the IRA, which although designed to limit out-of-pocket expenses, have concurrently introduced a complex dynamic for the insurers. The Act’s provisions, including caps on patient spending and closer regulation of drug pricing within Part D plans, impose constraints on profit margins and risk management strategies for private insurance entities. Consequently, some insurers have chosen to retreat from the market altogether rather than operate under these newly imposed financial parameters, creating a contraction in available plan options for beneficiaries.

Such market exits pose multifaceted challenges for Medicare recipients. Foremost among these is the risk of coverage disruption, as beneficiaries whose insurers leave the market must transition to alternative plans, which may not match their prior plans in terms of formulary coverage, premiums, or provider networks. This forced migration not only introduces logistical inconveniences but also threatens continuity in medication regimens—a critical factor given the chronic illnesses and complex therapeutics common in the senior population.

The implications extend beyond individual experiences to the broader landscape of Medicare Part D competition. Reduced insurer participation undermines market competition, which historically has been instrumental in driving down premiums and fostering innovation in plan offerings. With diminished competitive pressure, there is concern that remaining insurers could exert greater pricing power, potentially leading to heightened costs for beneficiaries and Medicare alike.

Dr. Benjamin N. Rome, MD, MPH, the senior author affiliated with the Program On Regulation Therapeutics, and Law (PORTAL) at Brigham and Women’s Hospital, emphasizes this unintended tradeoff. He notes that while the $2,000 out-of-pocket cap provides a clear benefit by curbing annual drug expenses, the ripple effect of insurer exits risks compromising the stability and accessibility of the Part D market. Millions could face the prospect of reassessing their drug plans under compressed time frames and limited choices, inducing stress and potential lapses in therapy adherence.

Lead author Christopher L. Cai, MD, also from PORTAL, highlights legislative measures that may be necessary to counterbalance these effects. Suggestions include lowering the legally established maximum deductible—which currently stands at $590—to mitigate patients’ upfront costs and prevent excessive financial strain before the out-of-pocket cap is reached. Additionally, introducing a public Part D standalone plan is proposed as a mechanism to inject competition into the market, offering beneficiaries an alternative to private insurers and potentially stabilizing plan availability and affordability.

The study’s analysis leverages detailed enrollee-level data, enabling granular observation of insurer retention rates and beneficiary displacement across the transitional years. The year-over-year increase in insurer exits is startling not only in scale but in pace, reflecting the immediate market adjustments following the implementation of IRA provisions. This underlines the sensitivity of private insurers to regulatory shifts and the importance of thoughtful policy design to anticipate secondary market effects.

Beyond the numbers, the research underscores a broader policy dilemma: how to balance cost containment for patients with preserving a competitive insurance landscape that encourages quality and choice. The IRA’s intent to shield seniors from catastrophic drug costs is laudable, yet the mechanism by which this end is achieved must account for insurer incentives and systemic sustainability.

The study also raises fundamental questions about patient autonomy and informed decision-making. When beneficiaries are compelled by insurer exits to switch plans, the associated administrative burdens may hinder their ability to make optimal choices. Notably, seniors may find themselves navigating complicated formularies, differing co-payment structures, and altered pharmacy networks, all of which can affect medication adherence and health outcomes.

Furthermore, the detected trend indicates the potential for exacerbated inequities among Medicare Part D enrollees. Vulnerable populations, including those with limited health literacy or mobility challenges, may be disproportionately disadvantaged by rapid plan churn and decreased market options, intensifying existing disparities in access to care.

Given these insights, the study calls for proactive oversight and policy interventions. Monitoring insurer behavior post-IRA implementation is critical to identify emerging market patterns and prevent destabilization. Moreover, fostering transparent communication channels between regulators, insurers, and beneficiaries is vital to facilitate smoother transitions when insurer exits occur.

In conclusion, the Inflation Reduction Act’s redesign of Medicare Part D prescriptions has delivered a crucial benefit by capping out-of-pocket spending; however, it has simultaneously triggered accelerated insurer withdrawals that threaten program stability. The resulting diminution of plan options and potential disruption in medication adherence underscores the need for Congress and regulatory agencies to consider stabilizing measures, including deductible adjustments and public plan options. As the healthcare community continues to grapple with balancing affordability and accessibility, this study illuminates the complex interdependencies inherent in prescription drug policy reform.

Subject of Research: Medicare Part D insurer exits following the Inflation Reduction Act reforms and their impact on beneficiaries.

Article Title: Insurer Exits After the Inflation Reduction Act Part D Redesign

News Publication Date: 14-May-2025

Web References: http://dx.doi.org/10.1001/jama.2025.7289

References: Cai, C. L. et al. “Insurer Exits After the Inflation Reduction Act Part D Redesign” JAMA DOI: 10.1001/jama.2025.7289

Keywords: Health care policy, Medicare Part D, Inflation Reduction Act, prescription drug affordability, insurer exits, medication adherence, patient out-of-pocket costs, health insurance market dynamics